Horizon Therapeutics Public - Stock Price History | HZNP

Historical daily share price chart and data for Horizon Therapeutics Public since 2021 adjusted for splits. The latest closing stock price for Horizon Therapeutics Public as of September 24, 2021 is 110.37.
  • The all-time high Horizon Therapeutics Public stock closing price was 110.37 on September 24, 2021.
  • The Horizon Therapeutics Public 52-week high stock price is 111.70, which is 1.2% above the current share price.
  • The Horizon Therapeutics Public 52-week low stock price is 66.41, which is 39.8% below the current share price.
  • The average Horizon Therapeutics Public stock price for the last 52 weeks is 88.23.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Horizon Therapeutics Public Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 55.1527 36.3800 84.3900 24.8700 73.1500 102.07%
2019 26.4398 19.9300 36.6700 19.4900 36.2000 85.26%
2018 17.1701 15.0200 22.4400 13.2400 19.5400 33.84%
2017 13.8394 16.8900 18.0900 9.6450 14.6000 -9.77%
2016 17.8396 21.0700 23.1900 13.4100 16.1800 -25.33%
2015 25.0338 12.8000 38.4500 12.8000 21.6700 68.11%
2014 12.4322 7.6100 17.3500 7.6100 12.8900 69.16%
2013 3.2118 2.4100 7.7100 1.9900 7.6200 227.04%
2012 3.9786 4.2000 8.3000 2.1300 2.3300 -41.75%
2011 7.0953 9.1500 9.1500 4.0000 4.0000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $24.733B $2.200B
Horizon Therapeutics PLC is a biopharmaceutical company. It is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines which address unmet medical needs. The Company markets medicines through its orphan, rheumatology and primary care business units. Horizon Therapeutics PLC, formerly known as Horizon Pharma Public Limited Company, is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71